CA2718676A1 - Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator - Google Patents

Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator Download PDF

Info

Publication number
CA2718676A1
CA2718676A1 CA2718676A CA2718676A CA2718676A1 CA 2718676 A1 CA2718676 A1 CA 2718676A1 CA 2718676 A CA2718676 A CA 2718676A CA 2718676 A CA2718676 A CA 2718676A CA 2718676 A1 CA2718676 A1 CA 2718676A1
Authority
CA
Canada
Prior art keywords
hydroxy
halo
mono
alkoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2718676A
Other languages
English (en)
French (fr)
Inventor
Alan S. Verkman
Nitin D. Sonawane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CA2718676A1 publication Critical patent/CA2718676A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CA2718676A 2008-04-04 2009-04-03 Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator Abandoned CA2718676A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4265108P 2008-04-04 2008-04-04
US61/042,651 2008-04-04
PCT/US2009/039566 WO2009146144A2 (en) 2008-04-04 2009-04-03 Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
CA2718676A1 true CA2718676A1 (en) 2009-12-03

Family

ID=41133847

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2718676A Abandoned CA2718676A1 (en) 2008-04-04 2009-04-03 Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator

Country Status (10)

Country Link
US (1) US20090253799A1 (cg-RX-API-DMAC10.html)
EP (1) EP2288592A2 (cg-RX-API-DMAC10.html)
JP (1) JP2011516499A (cg-RX-API-DMAC10.html)
KR (1) KR20110004413A (cg-RX-API-DMAC10.html)
AU (1) AU2009251519A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0910416A2 (cg-RX-API-DMAC10.html)
CA (1) CA2718676A1 (cg-RX-API-DMAC10.html)
MX (1) MX2010010783A (cg-RX-API-DMAC10.html)
TW (1) TW200946129A (cg-RX-API-DMAC10.html)
WO (1) WO2009146144A2 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509282A (pt) * 2004-03-30 2007-09-18 Univ California compostos contendo hidrazida inibidores de cftr e seus usos
US8552067B2 (en) * 2006-12-22 2013-10-08 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses therefor
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
JP2011517674A (ja) * 2008-03-25 2011-06-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 嚢胞性線維症膜コンダクタンス制御因子の水溶性小分子阻害剤
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
EP2278879B1 (en) 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131952A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising thiazole derivatives
US20090264481A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Oxadiazole Derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131956A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazole derivatives
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2464354B1 (en) 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
USRE48842E1 (en) 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
JPWO2019088270A1 (ja) * 2017-11-02 2020-12-03 宇部興産株式会社 蛋白分解酵素の双頭型阻害剤
KR20220046544A (ko) 2019-06-12 2022-04-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 답즙산 설사를 치료하는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE103902T1 (de) * 1982-05-07 1994-04-15 Ciba Geigy Ag Verwendung von chinolinderivaten zum schuetzen von kulturpflanzen.
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20050023974A1 (en) 2003-08-01 2005-02-03 Universal Display Corporation Protected organic electronic devices and methods for making the same
BRPI0509282A (pt) * 2004-03-30 2007-09-18 Univ California compostos contendo hidrazida inibidores de cftr e seus usos
US8552067B2 (en) * 2006-12-22 2013-10-08 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses therefor

Also Published As

Publication number Publication date
TW200946129A (en) 2009-11-16
US20090253799A1 (en) 2009-10-08
EP2288592A2 (en) 2011-03-02
MX2010010783A (es) 2010-11-12
KR20110004413A (ko) 2011-01-13
JP2011516499A (ja) 2011-05-26
AU2009251519A1 (en) 2009-12-03
WO2009146144A3 (en) 2010-01-28
WO2009146144A2 (en) 2009-12-03
BRPI0910416A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
AU2009251519A1 (en) Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator
EP2117601A2 (en) Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
JP5221341B2 (ja) ４−または５−アミノサリチル酸誘導体
JP4344235B2 (ja) タキソール増強剤化合物
JP4344234B2 (ja) タキソール増強剤化合物
JPH07501539A (ja) Ｎ，ｎ’−ジアセチルシスチンの有機塩
JP2008542209A5 (cg-RX-API-DMAC10.html)
JP2016531871A (ja) 粘膜炎を治療および／または予防するための方法および組成物
SG11202106117SA (en) Cromolyn esters and uses thereof
EP2521707A1 (en) Bisphenol derivatives and their use as androgen receptor activity modulators
BR112013015174A2 (pt) compostos de tio-semicarbazona e aplicação no tratamento de cancer
ZA200200464B (en) Phosphate transport inhibitors.
US20240374561A1 (en) Method for preventing nitration of tyrosine residues in hepatocyte growth factor using trisulfide compound
AU2005299385B2 (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
Smith et al. The action of certain sulfonamides, sulfones and related phosphorus compounds in experimental tuberculosis
CN109982703A (zh) 用谷氨酰胺酶抑制剂的组合疗法
CN107021961B (zh) 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
JP2009539777A5 (cg-RX-API-DMAC10.html)
CZ20023701A3 (cs) Inhibitory transportu fosfátu
CA2740568A1 (en) Compositions and methods for treating or preventing hypoxic or ischemic injury
KR20190114955A (ko) Mtor-deptor 상호작용의 저해제 및 이의 사용 방법
TWI811116B (zh) 含硒元素的查爾酮化合物及其製備方法、包含其的醫藥組合物、以及用於製備預防或治療大腸癌之醫藥組合物的用途
ES2690852T3 (es) Compuestos de complejo de Fe(III) para el tratamiento y la profilaxis de fenómenos por deficiencia de hierro y anemias por deficiencia de hierro
CN103183722A (zh) 一种乙二醛酶ⅰ抑制剂及其制备方法和医药用途
KR102701383B1 (ko) 리포-하이드록삼산 유도체 및 이의 약학적 용도

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20150407